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Background
Prostate cancer (PCa) is the second most common can-
cer, and the fifth leading cause of cancer related death
among men worldwide. Immunotherapy designed to
induce tumor cell specific immune responses capable of
destroying tumor cells has emerged as a promising treat-
ment modality in solid malignant tumors. Clinical and
preclinical trials have shown that docetaxel chemotherapy
can be combined with DCVAC/PCa immunotherapy
without impairing the immune response, while Kaplan-
Meier analyses showed that patients had a lower risk of
death compared with both MSKCC (Hazard Ratio 0.26,
95% CI: 0.13–0.51) and Halabi (Hazard Ratio 0.33, 95%
CI: 0.17–0.63) predictions[1].
Methods
VIABLE is a randomized, double-blind, placebo-controlled,
parallel-group, Phase III study to evaluate, in patients with
mCRPC eligible for first-line docetaxel chemotherapy, the
efficacy and safety of docetaxel chemotherapy plus
DCVAC/PCa (active cellular immunotherapy based on
activated dendritic cells) versus docetaxel chemotherapy
plus placebo. The study was initiated in May 2014 and
plans to enroll almost 1200 patients at approximately 230
sites globally. Eligible patients are required to present with
metastatic castrate-resistant PCa defined by both the pre-
sence and progression of the disease, maintenance of a cas-
trate state (less than 50 ng/dl), ECOG score 0-2, and
adequate hematologic, hepatic and renal functions. All
patients will receive standard of care docetaxel plus predni-
sone, and will be randomized 2:1 to DCVAC/PCa or pla-
cebo. Patients will be stratified by region, previous therapy
and ECOG status. The primary endpoint is overall survival
(OS). Assuming proportional hazards, a two-tailed level of
significance of 0.05 and 80% power will be applied.
Additionally this design assumes an exponential survival
distribution to detect a HR = 0.792 in favor of the
DCVAC/PCA group. Registration number NCT02111577,
EudraCT number 2012-002814-38.
Trial registration
ClinicalTrials.gov identifier NCT02111577. EudraCT
number 2012-002814-38.
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